<%= message.delivery.preHeader %>
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  
View online
TheirHemTruthHurts Logo
Why do trade-offs and challenges persist in hemophilia A despite advancements?
Photo of three people: Pediatric hematologists Dr Tami Singleton and Dr Ben Samelson-Jones, and Brian Almquist, who lives with severe hemophilia A.
Leading HCPs who treat hemophilia A—and people who live with it—have a lot to say about the current state of hemophilia A care.
Bringing together healthcare providers, a pharmacist, and a person living with hemophilia A to share their unique perspectives on the state of hemophilia A care, this video discusses unmet needs, hidden trade-offs, and the potential benefits of increasing shared decision-making.
See how your peers are approaching hemophilia A discussions — and compare them with your own perspectives.
Watch the video
Three photos in a horizontal line, each of a different person being interviewed in a conference setting.
What other topics are driving conversations?
Your peers in hemophilia A are also discussing these topics, including:
  Why do bleeds persist despite prophylaxis therapy?
  Do patients want less frequent dosing options?
  Which patients might be dissatisfied with treatment?
  What trade-offs in administration preferences and bleed protection are patients making?
Could their opinions offer you a fresh perspective?
Explore peer views
Icon of a document with a check mark inside an open envelope.
Stay current with the latest info
The world of hemophilia A treatment is changing. Get updates and communications from Novo Nordisk as they become available.
Sign up
<%@ include view='hcpColoradoFooter' %>
Please do not respond to this email. If you would like to contact us, please click here or call 1-877-744-2579.
UNSUBSCRIBE NOTICE
If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2026 Novo Nordisk  All rights reserved.  US26HRBD00113  July 2026		 Novo Nordisk logo.